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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S186physical component of quality of life. Particularly severe back pain and
dizziness in combination with falling, and 5 or more comorbidities
should be taken into account in OA patients undergoing joint replace-
ment surgery, in order to tune to expectations, satisfaction and outcome
after surgery.
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THE NEED FOR CAUTION IN THE SELECTION AND INTERPRETATION
OF MEASURES OF FUNCTION FOR PATIENTS WITH SEVERE HIP AND
KNEE PROBLEMS
E. Lenguerrand y, V. Wylde y, L. Brunton y, R. Gooberman-Hill y,
P. Dieppe z, A. Blom y. yUniv. of Bristol, Bristol, United Kingdom; zUniv. of
Exeter, Exeter, United Kingdom
Purpose: Joint replacement is a common operation, predominantly
provided to older adults with osteoarthritis. Reduced function is one of
themain indications for joint replacement, and recovery of function one
of its main objectives. Adequate assessment of function is critical to help
both health care professionals and patients decide upon treatment
options and to enable evaluation of the effectiveness of joint
replacement.
Physical function is commonly assessed in three ways: patient-reported
outcome measures (PROMs), performance tests, and clinician-admin-
istered measures. It is recommended that several types of these
measures should be used concurrently to capture an extended picture
of function but patient burden, resources and logistical constraints
mean that such an approach is seldom feasible. Moreover, most of the
tools in use do not clearly differentiate between impairments, activity
limitations and participation restrictions, and it is unclear to what
extent each measure describes them, which in turn has implications as
to their substitutability and comparability. The picture is further com-
plicated by the effects of multi-morbidity and patient characteristics on
functional measures.
The aims of this research were twofold: 1) to describe the correlations
between a variety of commonly used functional measures collected on
the same group of older patients listed for hip or knee replacement, and
2) explore associations between these measures and patient
characteristics.
Methods: 1,451 patients listed for primary or revision hip or knee
replacement at a single high-volume orthopaedic centrewere invited to
take part in a study of function before joint replacement. 264 agreed to
do so and provided their informed consent.
Participants were asked to complete a postal questionnaire about their
age, gender, BMI, living arrangements, education level and working
status. They completed the Functional Co-morbidity Index and the
Hospital Anxiety and Depression Scale. The severity of arthritis was
derived as a count of affected joints other than the joint listed for sur-
gery. Two PROMs were also completed, the Western Ontario McMaster
Arthritis Index pain and function scales and the Aberdeen Impairment,
Activity Limitation and Participation measure.
Participants were also invited to an appointment during which clini-
cian-administered measures and performance tests were performed.
These comprised the Harris Hip Score (HHS) or the American Knee
Society Score (AKSS), which were completed by a research nurse. The
performance tests were a timed 20 metre walk, the get-up-and-go test,
step tests (20 and 30 cm high blocks), and a single stance balance test.
The relationships between the functional measures were assessed with
Spearman Rank coefﬁcient, point-biserial coefﬁcient or Cramer’s V
statistic. The association between participants’ characteristics and
functional measures were investigated with linear regression or
modiﬁed Poisson regression with robust error variance. Individual
patient characteristics were ﬁrst considered in univariate models and
then in multivariate analyses to determine if their effects were con-
founded by other factors. The analyses were conducted separately for
hip and knee patients.
Results: Strong to moderate correlations were found within PROMs (r
¼ 0.63 to 0.88) and within performance tests, but correlations were
weaker between these two assessment approaches (r ¼ 0.17 to 0.65).
The HHS correlated better with PROMs (r w0.70) than performance
tests (r¼ 0.38 to 0.67); poor correlations were foundwith the AKSS and
other functional measures (r ¼ 0.18 to 0.28).Patients’ psychological well-being was associated with PROMs (p-value
<0.0001) but not with performance tests. Age was associated with
performance tests (p-values ranging from <0.05 to <0.0001) but not
with PROMs. Pain was strongly associated with function irrespectively
of the measurement method. Other patient characteristics had weak or
no association with function.
Conclusions: We found that PROMs, performance tests and clinician-
administered measures provide information on different aspects of
function. This study also shows that associations between function and
patient characteristics differed according to the measurement approach
used. The functional limitations caused by joint pathology are entan-
gled with the limitations resulting from ageing when measured with
performance tests; while psychological status seems to play an
important role in patients’ self-reported perception of functional ability.
Both objective and subjective measures need to be adjusted for pain to
enable appropriate interpretation.
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CLINIMETRICS OF THE STAIR CLIMB TEST IN THE AMSTERDAM
COHORT
J.H. Abbott y, M. van der Esch z, L.D. Roorde z, J. Knoop z,
M. van der Leeden z, W.F. Lems z. yUniv. of Otago, Dunedin, New Zealand;
zAmsterdam Rehabilitation Res. Ctr., Reade, Amsterdam, Netherlands
Purpose: OARSI recently published recommendations for physical
performance tests in hip or knee osteoarthritis (OA). A test of stair
climbing was recommended, but the authors could not recommend a
speciﬁc stair climbing test or report clinimetric properties due to a lack
of data in the literature. The purpose of this study was to describe
clinimetric properties of the stair climb test (SCT) in people with knee
OA. SCT-up and SCT-down were reported separately, to reveal poten-
tially differing clinimetric properties.
Methods: Baseline and 2-year follow-up data from the Amsterdam
Cohort (n ¼ 200) were analyzed. Construct validity (convergent) was
estimated using Pearson’s correlation coefﬁcients between the SCTs and
the Western Ontario and McMaster Osteoarthritis index (WOMAC).
Smallest detectable change (SDC) at the 90% conﬁdence level was cal-
culated from the standard error of measurement (SEM). We report the
difference in SCT means between responders and non-responders at
different cut-points of WOMAC Total scale score (WOMAC-T); WOMAC
physical function subscale score (WOMAC-PF); and knee extensor
strength change reported in the literature. Minimum important change
(MIC) was calculated using receiver operating characteristics (ROC)
curve methodology, from baseline and follow-up data. The change data
was dichotomised into responders and non-responders using cut-off
criteria for each of the following external references: WOMAC-T;
WOMAC-PF; and knee extensor strength change. MIC estimates for
small, medium and large change are reported for each of the cut-points
sourced from the literature. Construct validity (discriminant) was esti-
mated using the area under the ROC curve (AUC), with an a priori sig-
niﬁcance level of .80.
Results: Construct validity (convergent) was moderate (.39) against
WOMAC-T and WOMAC-PF (.41). SDC (90%) was larger for SCT-down
(3.75 sec) than for SCT-up (1.63 sec). The proportion of patients
achieving MCID on the WOMAC-T was 44.5% and for small change
and 33.5% for moderate change. For WOMAC-T, the difference in
mean SCT time for those who achieved small change in SCT-up was
.82 sec (95%CI .27, 1.4) and .93 sec (.35, 1.5) for moderate change.
The difference in SCT-up means between responders and non-res-
ponders on the WOMAC-PF were .87 (.27, 1.50), .89 (.08, 1.38) and
.74 (.09, 1.38) for small, moderate and large changes, respectively. For
knee extensor strength, the differences in SCT-up means were: .46
(.08, .99), .43 (.15, 1.01), .36 (.31, 1.03), and .09 (.66, .84) for
small, moderate, medium and large changes respectively. MIC for the
SCT-up was .40 for small change and 0.70 for moderate change in
WOMAC-T. MIC for the SCT-up based on small, moderate and large
changes in WOMAC-PF were .40, .40 and .30, respectively. MIC
for the SCT-up based on small, moderate, medium and large changes
in knee extensor strength was .70 at all levels. MDC and MIC
values for the SCT-down were larger or equal in 7 of 9 analyses. AUC
values did not exceed .75 for any ROC analysis.
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S187Conclusions: These data indicate that the SCT was not responsive to
change in this cohort over 2 years, and did not adequately discriminate
between patients identiﬁed as responders or non-responders, at any
level of theWOMAC-T, WOMAC-PF or knee extensor strength criteria, in
a cohort of people with knee OA. The difference in SCT means between
responders and non-responders did not exceed SDC (90%). The SCT
failed to demonstrate construct validity for discriminating between
responders or non-responders on any level of the WOMAC-T, WOMAC-
PF or knee extensor strength criteria. SCT-down performed worse than
SCT-up. We cannot recommend the SCT as an outcome measure in
cohort studies of people with knee OA. Results may differ in trials with
protocolized interventions and shorter follow-up.
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PAIN IN ACTIVITY EVALUATION (PACE) IN KNEE OSTEOARTHRITIS –
RESPONSIVENESS AND CONCURRENT VALIDITY OF TENTATIVE
MEASURES IN A RANDOMIZED CONTROLLED EXERCISE STUDY
L. Klokker, E. Bandak, C. Bartholdy, H. Bliddal, M. Henriksen. The Parker
Inst., Frederiksberg, Denmark
Purpose: Pain and physical function are recommended outcomes in
knee osteoarthritis (OA) treatment. Patient Reported Outcome Meas-
ures (PROM) are standard, sometimes supplemented with performance
tests. Pain and function are closely related but this clinically relevant
interaction is not accounted for in existing outcome measures to knee
OA. Therefore we developed two versions of a tentative standardized
measure consisting of patient reported pain intensity after 6 and 20
minutes of walking respectively, called Pain in ACtivity Evaluation
(PACE6 and PACE20). The purposewas to investigate the responsiveness
to changes of PACE6 and PACE20 after a 12 week exercise program, and
to explore the concurrent validity of PACE6 and PACE20 against existing
measures of pain and function.Table 1
Baseline scores, changes at follow-up, differences between groups and effect sizes
EXE CON
BaselineMean
(SD)
Mean change at
follow-up* (95%CI)
BaselineMean
(SD)
Mean change at
follow-up* (95%CI)
Mean difference
(95%CI)
p-value Effect size (95% CI)
PACE20, NRS/km 18.3 (17.0) 8.3 (12.7 to 3.9) 14.2 (13.2) 1.9 (6.7 to 2.9) 6.4 (0.1 to 12.9) 0.0537 0.66 (0.43 to 0.88)
Pre 20MW pain,
0–100
12.4 (20.7) 0.3 (1.1 to 0.5) 6.4 (11.0) 0.6 (1.5 to 0.3) 0.3 (1.5 to 0.9) 0.6409 0.16 (0.06 to 0.37)
Post 20MWpain,
0–100
21.5 (26.9) 8.7 (14.9 to 2.4) 19.1 (19.3) 3.3 (10.1 to 3.5) 5.3 (3.9 to 14.6) 0.2496 0.39 (0.17 to 0.60)
PACE6, NRS/km 47.6 (39.6) 26.5 (42.7 to 10.3) 43.6 (48.2) 1.8 (15.4 to 18.9) 28.3 (4.6 to 51.9) 0.0206 0.83 (0.58 to 1.07)
Pre 6MW pain,
0–100
13.3 (17.8) 1.2 (1.8 to 0.6) 10.2 (17.4) 0.8 (1.4 to 0.1) 0.4 (0.4 to 1.3) 0.3230 0.33 (0.12 to 0.55)
Post 6MWpain,
0–100
22.3 (17) 12.5 (21.0 to 3.9) 21.5 (22.2) 2.0 (7.3 to 11.3) 14.5 (1.9 to 27.1) 0.0259 0.77 (0.51 to 1.00)
6MW, m 507.3 (99.3) 5.9 (41.0 to 52.8) 546.2 (74.9) 0.3 (50.7 to 51.3) 5.6 (75.7 to 64.5) 0.8717 0.05 (0.16 to 0.27)
KOOSpain, 0–100 55.1 (16.5) 6.8 (2.4 to 11.1) 59.0 (10.4) 1.4 (6.0 to 3.1) 8.2 (14.5 to 1.9) 0.0125 0.87 (0.64 to 1.10)
KOOSadl, 0–100 62.9 (15.6) 5.1 (0.2 to 10.0) 73.6 (13.2) 0.2 (5.0 to 5.4) 4.8 (12.2 to 2.6) 0.1919 0.44 (0.22 to 0.66)
* Adjusted for baseline values.
Table 2
Spearman correlation coefﬁcients
6MW KOOSpain KOOSadl
PACE20, NRS/km 0.271 0.588* 0.486*
Pre20MWpain, 0–100 0.079 0.505* 0.380*
Post20MWpain, 0–100 0.123 0.425* 0.297
PACE6, NRS/km 0.580* 0.357* 0.447*
Pre6MWpain, 0–100 0.484* 0.477* 0.502*
Post6MWpain, 0–100 0.467* 0.314 0.384*
*Statistical signiﬁcance level at p < 0.05.Methods: We used data from a random subgroup that completed
the PACE6 and PACE20, nested in an assessor blinded randomized
controlled trial (NCT01545258) comparing 12 weeks of supervised
exercise 3 times weekly (EXE) with a no attention control group
(CON). PACE6 is the 6-minutes walking test (6MW), i.e. walking as
fast as possible for 6 minutes, including pain rating on a 0–100
Numeric Rating Scale before (pre6MWpain) and immediately after
(post6MWpain). The PACE6 score was deﬁned as post6MWpain
divided by the distance walked in km (6MW), and scored in NRS/
km. The PACE20 score was deﬁned as pain rated on a 0–100 NRS
immediately after walking on a treadmill at a constant self-selected
comfortable speed for 20 minutes (post20MWpain), divided by the
distance walked in km, and scored in NRS/km. Pain was also rated
before the test (pre20MWpain). In PACE20 the baseline walking
speed was used at the follow-up visit. Further, the Knee injury andOsteoarthritis Outcome Score (KOOS) were assessed at baseline and
follow-up. We used the pain and activities of daily living (ADL)
subscales for this study. Effects of exercise on the outcomes were
assessed by ANCOVA adjusting for baseline values,
comparing changes from baseline between EXE and CON groups.
To explore concurrent validity of the PACE6 and PACE20 associa-
tions between all baseline parameters were assessed using Spear-
man’s rank correlation. All analyses were performed on the per
protocol population deﬁned as participants included in the RCT
analysis with complete PACE6 and PACE20 at baseline and follow-
up.
Results: A total of 37 participants deﬁned the per protocol population
(EXE ¼ 20, CON ¼ 17). Mean baseline scores of all outcomes are shown
in Table 1. There were signiﬁcant group differences in the changes in
PACE6, post6MWpain and KOOSpain in favor of EXE, but not in the other
outcomes (Table 1). Baseline scores of both PACE6 and PACE20 were
correlated to KOOSpain and KOOSadl, while only PACE6 was correlated
to the 6MW (Table 2).
Conclusions: The PACE6 was responsive to change in pain (NRS/km)
after 12 weeks of exercise and able to detect a signiﬁcant difference
between exercise and control groups. In contrast the lack of
responsiveness of pre-test pain scores supports the relevance of an
activity based pain measure. The PACE20 was less responsive,
implying that pain in activity can be assessed by one single pain
rating immediately after 6 instead of 20 minutes of walking, at least
if the speed is the fastest possible. This is a promising ﬁnding
regarding feasibility, making use of even shorter tests probable. The
associations between PACE6 and both patient reported pain and
function (KOOS), and observed performance (6MW) show concurrent
validity, and suggest that PACE6 captures both a pain and a func-
tional/performance aspect. While the PACE still needs reﬁnement
these results encourage the pursuit of developing a feasible stand-ardized measure that reﬂects the interaction between pain and
function.
